X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2775) 2775
Publication (176) 176
Newsletter (76) 76
Book Review (60) 60
Newspaper Article (31) 31
Magazine Article (20) 20
Book Chapter (17) 17
Book / eBook (6) 6
Conference Proceeding (4) 4
Trade Publication Article (3) 3
Data Set (1) 1
Dissertation (1) 1
Government Document (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2009) 2009
heparin (1128) 1128
index medicus (1056) 1056
female (810) 810
male (735) 735
anticoagulants - therapeutic use (675) 675
molecular-weight heparin (665) 665
middle aged (542) 542
anticoagulants (516) 516
aged (500) 500
deep-vein thrombosis (470) 470
heparin - therapeutic use (430) 430
unfractionated heparin (430) 430
prevention (426) 426
venous thromboembolism (419) 419
heparin, low-molecular-weight - therapeutic use (402) 402
thromboembolism (394) 394
adult (373) 373
hematology (365) 365
cost-benefit analysis (364) 364
risk factors (359) 359
treatment outcome (354) 354
pharmacology & pharmacy (332) 332
peripheral vascular disease (329) 329
surgery (324) 324
thrombosis (310) 310
anticoagulants - administration & dosage (304) 304
anticoagulants - economics (304) 304
animals (293) 293
pulmonary-embolism (279) 279
cardiac & cardiovascular systems (277) 277
anticoagulants - adverse effects (261) 261
enoxaparin (248) 248
heparin - administration & dosage (248) 248
analysis (242) 242
prophylaxis (231) 231
venous thrombosis - prevention & control (226) 226
medicine, general & internal (225) 225
venous thrombosis (222) 222
drug therapy (214) 214
heparin - adverse effects (204) 204
heparin, low-molecular-weight - economics (202) 202
aged, 80 and over (200) 200
medicine & public health (200) 200
fibrinolytic agents - therapeutic use (197) 197
research (191) 191
pulmonary embolism (189) 189
heparin - economics (188) 188
retrospective studies (186) 186
warfarin (182) 182
venous thrombosis - drug therapy (179) 179
glycosaminoglycans (178) 178
health aspects (177) 177
prospective studies (177) 177
venous thromboembolism - prevention & control (177) 177
postoperative complications - prevention & control (172) 172
thromboembolism - prevention & control (172) 172
mortality (170) 170
care and treatment (169) 169
anticoagulation (167) 167
management (167) 167
therapy (162) 162
risk (159) 159
heparin, low-molecular-weight - administration & dosage (157) 157
cost-effectiveness (156) 156
time factors (155) 155
enoxaparin - therapeutic use (137) 137
low-molecular-weight heparin (135) 135
thromboprophylaxis (132) 132
complications (128) 128
randomized controlled trials as topic (127) 127
risk assessment (127) 127
hemorrhage - chemically induced (125) 125
patients (125) 125
pregnancy (121) 121
venous thrombosis - economics (118) 118
metaanalysis (116) 116
pulmonary embolism - prevention & control (116) 116
trial (116) 116
deep vein thrombosis (115) 115
cancer (114) 114
united states (111) 111
warfarin - therapeutic use (110) 110
low molecular weight heparin (109) 109
practice guidelines as topic (109) 109
clinical trials as topic (108) 108
diagnosis (108) 108
double-blind (108) 108
heparin, low-molecular-weight - adverse effects (107) 107
heparin-induced thrombocytopenia (103) 103
cardiology (102) 102
costs and cost analysis (101) 101
usage (101) 101
adolescent (100) 100
drug costs (99) 99
dosage and administration (98) 98
medicine (98) 98
enoxaparin - economics (97) 97
total hip-replacement (96) 96
health care sciences & services (95) 95
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2825) 2825
French (30) 30
German (28) 28
Russian (11) 11
Spanish (10) 10
Swedish (5) 5
Portuguese (4) 4
Finnish (2) 2
Japanese (2) 2
Korean (2) 2
Slovak (2) 2
Czech (1) 1
Dutch (1) 1
Hungarian (1) 1
Italian (1) 1
Norwegian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Kidney International, ISSN 0085-2538, 03/2018, Volume 93, Issue 3, pp. 753 - 760
Catheter-related infections and dysfunction are the main catheter complications causing morbidity and mortality in hemodialysis patients. However, there are no... 
hemodialysis | tunneled catheter | taurolidine | catheter dysfunction | catheter-related infection | urokinase | ONCOLOGY-GROUP | METAANALYSIS | 4-PERCENT | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ANTIMICROBIAL LOCK | HEPARIN | TRISODIUM CITRATE | BACTEREMIA | UROLOGY & NEPHROLOGY | VASCULAR ACCESS | Drug Costs | Urokinase-Type Plasminogen Activator - therapeutic use | Prospective Studies | Taurine - economics | Humans | Middle Aged | Anticoagulants - economics | Heparin - therapeutic use | Male | Renal Dialysis - economics | Thiadiazines - adverse effects | Catheters, Indwelling - economics | Equipment Design | Thiadiazines - therapeutic use | Catheter-Related Infections - prevention & control | Thiadiazines - economics | Cost Savings | Austria | Time Factors | Fibrinolytic Agents - therapeutic use | Catheters, Indwelling - adverse effects | Catheter Obstruction - etiology | Heparin - economics | Adult | Female | Catheter-Related Infections - diagnosis | Taurine - therapeutic use | Catheterization, Central Venous - adverse effects | Taurine - adverse effects | Taurine - analogs & derivatives | Anti-Infective Agents - adverse effects | Catheter-Related Infections - economics | Risk Factors | Anti-Infective Agents - therapeutic use | Anticoagulants - therapeutic use | Central Venous Catheters - adverse effects | Treatment Outcome | Catheterization, Central Venous - economics | Central Venous Catheters - economics | Fibrinolytic Agents - economics | Catheter-Related Infections - microbiology | Cost-Benefit Analysis | Anti-Infective Agents - economics | Aged | Urokinase-Type Plasminogen Activator - economics | Catheter Obstruction - economics | Catheterization, Central Venous - instrumentation | Equipment Failure | Hypertension | Comorbidity | Hemodialysis | Cardiovascular disease | Infections | Catheters | Morbidity | Citric acid | U-Plasminogen activator | Studies | Microorganisms | Antibiotics | Diabetes | Kidney diseases | Heparin | Veins & arteries
Journal Article
JAMA, ISSN 0098-7484, 11/2014, Volume 312, Issue 20, pp. 2135 - 2145
Journal Article
Catheterization and Cardiovascular Interventions, ISSN 1522-1946, 02/2016, Volume 87, Issue 3, pp. 363 - 373
Background Outcomes with bivalirudin compare favorably with heparin ± GPIIb/IIIa receptor inhibition (heparin ± GPI) during percutaneous coronary intervention... 
congestive heart failure | percutaneous coronary intervention | bivalirudin | cost analysis | MORTALITY | PROGNOSTIC IMPACT | CARDIAC & CARDIOVASCULAR SYSTEMS | THROMBIN | GLOBAL REGISTRY | HEPARIN | TRIAL | ANGIOPLASTY | PROPENSITY SCORE METHODS | ACUTE MYOCARDIAL-INFARCTION | EVENTS GRACE | Drug Costs | Hospital Costs | Recombinant Proteins - therapeutic use | Platelet Aggregation Inhibitors - economics | United States - epidemiology | Length of Stay - economics | Percutaneous Coronary Intervention - mortality | Blood Transfusion - economics | Humans | Middle Aged | Anticoagulants - economics | Heparin - therapeutic use | Male | Recombinant Proteins - adverse effects | Young Adult | Time Factors | Aged, 80 and over | Heparin - economics | Adult | Female | Heart Failure - diagnosis | Hirudins - economics | Retrospective Studies | Heart Failure - economics | Platelet Aggregation Inhibitors - therapeutic use | Databases, Factual | Heart Failure - mortality | Peptide Fragments - economics | Blood Loss, Surgical - prevention & control | Heart Failure - complications | Hospital Mortality | Antithrombins - therapeutic use | Anticoagulants - therapeutic use | Treatment Outcome | Recombinant Proteins - economics | Antithrombins - economics | Antithrombins - adverse effects | Cost-Benefit Analysis | Hirudins - adverse effects | Aged | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Percutaneous Coronary Intervention - economics | Percutaneous Coronary Intervention - adverse effects | Transluminal angioplasty | Anticoagulants (Medicine) | Glycosaminoglycans | Cardiac patients | Patient outcomes | Medical care, Cost of
Journal Article
Thrombosis Research, ISSN 0049-3848, 02/2017, Volume 150, pp. 123 - 130
The comparative cost-effectiveness of all oral anticoagulants approved up to date has not been evaluated from the US perspective. The objective of this study... 
Anticoagulation | Cost-effectiveness | Atrial fibrillation | Non-vitamin K antagonist oral anticoagulants | CARDIOVASCULAR EVENTS | RIVAROXABAN | APIXABAN | MAJOR HEMORRHAGE | PROPHYLAXIS | DABIGATRAN | WARFARIN | MOLECULAR-WEIGHT HEPARIN | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | ISCHEMIC-STROKE | SYSTEMIC EMBOLISM | Dabigatran - adverse effects | Markov Chains | Pyrazoles - therapeutic use | Humans | Anticoagulants - economics | Warfarin - adverse effects | Warfarin - economics | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - adverse effects | Warfarin - therapeutic use | Atrial Fibrillation - economics | Pyridines - adverse effects | Rivaroxaban - adverse effects | Aged, 80 and over | Pyridones - economics | Rivaroxaban - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Rivaroxaban - economics | Thiazoles - economics | Quality-Adjusted Life Years | Stroke - prevention & control | Atrial Fibrillation - complications | Stroke - economics | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Pyrazoles - economics | Dabigatran - economics | Cost-Benefit Analysis | Pyridines - economics | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Prevention | Stroke (Disease) | Warfarin | Diet therapy | Anticoagulants (Medicine) | Medical care, Cost of
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 11/2004, Volume 44, Issue 9, pp. 1792 - 1800
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2008, Volume 52, Issue 22, pp. 1758 - 1768
Journal Article
Journal Article
Journal of Cardiothoracic and Vascular Anesthesia, ISSN 1053-0770, 2013, Volume 27, Issue 2, pp. 230 - 237
Objective To study the impact on postoperative costs of a patient's antithrombin levels associated with outcomes after cardiac surgery with extracorporeal... 
Anesthesia & Perioperative Care | Critical Care | antithrombin | cardiopulmonary bypass | extracorporeal circulation | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | OPERATIONS | REQUIRING CARDIOPULMONARY BYPASS | CORONARY-ARTERY-BYPASS | HEPARIN | HEMODILUTION | GRAFT-SURGERY | RESPIRATORY SYSTEM | COAGULATION | ANESTHESIOLOGY | PERIPHERAL VASCULAR DISEASE | COMPLICATIONS | CONSUMPTION | Drug Costs | Postoperative Complications - economics | Blood Transfusion - economics | Humans | Kidney Diseases - diagnosis | Middle Aged | Postoperative Care - economics | Intensive Care Units - economics | Postoperative Complications - blood | Cardiotonic Agents - economics | Male | Cardiac Surgical Procedures - adverse effects | Cardiac Surgical Procedures - economics | Thromboembolism - diagnosis | Cardiotonic Agents - therapeutic use | Drug Therapy - economics | Atrial Fibrillation - economics | Female | Myocardial Infarction - economics | Surveys and Questionnaires | Atrial Fibrillation - diagnosis | Myocardial Infarction - etiology | Length of Stay | Myocardial Infarction - diagnosis | Extracorporeal Circulation - adverse effects | Costs and Cost Analysis | Stroke - economics | Treatment Outcome | Postoperative Complications - epidemiology | Thromboembolism - etiology | Thromboembolism - economics | Stroke - etiology | Kidney Diseases - economics | Extracorporeal Circulation - economics | Spain - epidemiology | Antithrombins - blood | Atrial Fibrillation - etiology | Aged | Decision Trees | Kidney Diseases - etiology | Health Care Surveys | Coronary artery bypass | Sects
Journal Article
Thrombosis Research, ISSN 0049-3848, 2012, Volume 131, Issue 1, pp. 17 - 23
Journal Article
Value in Health, ISSN 1098-3015, 2011, Volume 14, Issue 5, pp. S89 - S92
Abstract Objectives To evaluate the direct costs of venous thromboembolism (VTE) treatment with unfractionated heparin (UFH) and low-molecular weight heparin,... 
Internal Medicine | heparin | deep venous thrombosis | utilization study | cost analysis | POPULATION | METAANALYSIS | MANAGEMENT | DEEP-VEIN THROMBOSIS | OUTPATIENT TREATMENT | MOLECULAR-WEIGHT HEPARIN | PULMONARY-EMBOLISM | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | ECONOMICS | INPATIENT | Drug Costs | Health Resources - utilization | Hospital Costs | Recurrence | Venous Thromboembolism - mortality | Prospective Studies | Anticoagulants - administration & dosage | Blood Transfusion - economics | Humans | Middle Aged | Anticoagulants - economics | Heparin - administration & dosage | Models, Economic | Heparin - adverse effects | Health Services Research | Enoxaparin - adverse effects | Hemorrhage - economics | Venous Thromboembolism - drug therapy | Cost Savings | Venous Thromboembolism - blood | Young Adult | Enoxaparin - administration & dosage | Hospitals, Teaching - economics | Time Factors | Aged, 80 and over | Brazil | Heparin - economics | Adult | Venous Thromboembolism - economics | Drug Administration Schedule | Enoxaparin - economics | Hemorrhage - therapy | Health Resources - economics | Logistic Models | Treatment Outcome | Anticoagulants - adverse effects | Chi-Square Distribution | Outcome and Process Assessment (Health Care) - economics | Blood Coagulation - drug effects | Adolescent | Aged | Drug Monitoring - economics | Hemorrhage - chemically induced | Hospitalization - economics
Journal Article
European Journal of Vascular & Endovascular Surgery, ISSN 1078-5884, 07/2018, Volume 56, Issue 1, pp. 87 - 93
Heparin coating has recently been shown to reduce the risk of graft failure in arterial revascularisation, at least transiently. The aim of this study was to... 
Blood vessel prosthesis | Cost benefit analysis | Randomised controlled trials | Peripheral arterial disease/surgery | Vascular patency | SURGERY | REGISTER | MULTICENTER | GUIDELINES | FEMOROPOPLITEAL | FRAMEWORK | PERIPHERAL VASCULAR DISEASE | QUALITY-OF-LIFE | HEALTH | Peripheral Arterial Disease - surgery | Anticoagulants - administration & dosage | Coated Materials, Biocompatible - economics | Humans | Middle Aged | Anticoagulants - economics | Heparin - administration & dosage | Male | Heparin - adverse effects | Prosthesis Design | Polytetrafluoroethylene - economics | Cost Savings | Blood Vessel Prosthesis - economics | Blood Vessel Prosthesis Implantation - adverse effects | Time Factors | Aged, 80 and over | Heparin - economics | Female | Popliteal Artery - surgery | Quality-Adjusted Life Years | Blood Vessel Prosthesis Implantation - instrumentation | Treatment Outcome | Peripheral Arterial Disease - economics | Anticoagulants - adverse effects | Blood Vessel Prosthesis Implantation - economics | Health Care Costs | Peripheral Arterial Disease - diagnosis | Cost-Benefit Analysis | Denmark | Quality of Life | Aged | Femoral Artery - surgery | Drugs | Polytetrafluoroethylene | Political corruption | Prosthesis | Long-term care of the sick | Standards | Prescribing | Coronary artery bypass | Implants, Artificial | Surgery | Analysis | Heparin | Medical care, Cost of
Journal Article